- Home
- SRV vs IPHA Comparison
SRV vs IPHA Comparison
Compare SRV & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- IPHA
- Stock Information
- Founded
- SRV 2007
- IPHA 1999
- Country
- SRV United States
- IPHA France
- Employees
- SRV N/A
- IPHA N/A
- Industry
- SRV Finance Companies
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SRV Finance
- IPHA Health Care
- Exchange
- SRV Nasdaq
- IPHA Nasdaq
- Market Cap
- SRV 185.8M
- IPHA 160.1M
- IPO Year
- SRV N/A
- IPHA 2019
- Fundamental
- Price
- SRV $43.77
- IPHA $2.19
- Analyst Decision
- SRV
- IPHA Strong Buy
- Analyst Count
- SRV 0
- IPHA 1
- Target Price
- SRV N/A
- IPHA $11.00
- AVG Volume (30 Days)
- SRV 33.9K
- IPHA 12.6K
- Earning Date
- SRV 01-01-0001
- IPHA 09-11-2025
- Dividend Yield
- SRV 13.38%
- IPHA N/A
- EPS Growth
- SRV N/A
- IPHA N/A
- EPS
- SRV N/A
- IPHA N/A
- Revenue
- SRV N/A
- IPHA $20,831,349.00
- Revenue This Year
- SRV N/A
- IPHA $278.51
- Revenue Next Year
- SRV N/A
- IPHA $70.16
- P/E Ratio
- SRV N/A
- IPHA N/A
- Revenue Growth
- SRV N/A
- IPHA N/A
- 52 Week Low
- SRV $30.73
- IPHA $1.29
- 52 Week High
- SRV $44.30
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SRV 59.59
- IPHA 59.91
- Support Level
- SRV $42.26
- IPHA $2.06
- Resistance Level
- SRV $44.45
- IPHA $2.28
- Average True Range (ATR)
- SRV 0.66
- IPHA 0.15
- MACD
- SRV 0.09
- IPHA 0.00
- Stochastic Oscillator
- SRV 62.35
- IPHA 33.03
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.